|
|
|
| Clinical effect of Atorvastatin Calcium combined with Silibinin in the treatment of non-alcoholic fatty liver disease |
| HE Xiaojun YANG Zhenyu DU Xilin▲ TAN Kai YANG Tao LU Jianguo |
| Department of General Surgery, Tangdu Hospital of the Fourth Military Medical University, Shaanxi Province, Xi'an 710038, China |
|
|
|
Abstract Objective To investigate the clinical effect of Atorvastatin Calcium combined with Silibinin in the treatment of non-alcoholic fatty liver disease. Methods One hundred and seventy patients with non-alcoholic fatty liver disease treated in Tangdu Hospital of the Fourth Military Medical University from July 2015 to March 2016 were selected and divided into observation group and control group by random number table method, with 85 cases in each group. On basis of routine treatment, the observation group was added with Atorvastatin Calcium 20 mg, once a day, Silibinin 70 mg, 3 times/d; on basis of routine treatment, the control group was only applied with Silibinin 70 mg, 3 times/d, for 24 weeks. The improvement of liver function and serum lipid levels of the two groups before and after treatment was compared, and the improvement of fatty liver was detected by image examination. Results After treatment, the levels of aspartate aminotransferase (ALT) and alanine transaminase (AST) in observation group were significantly lower than those before treatment, the differences were statistically significant (P ＜ 0.05); after treatment, the levels of ALT and AST in observation group were lower than those of control group, but the differences were not statistically significant (P ＞ 0.05). After treatment, the levels of triacylglycerol (TG) and total cholesterol (TC) were all significantly lower than those before treatment, and the levels of TG and TC in observation group were lower than those of control group, the differences were all statistically significant (all P ＜ 0.05). The CT value of observation group after treatment was higher than that of control group, the difference was statistically significant (P ＜ 0.05). Conclusion Atorvastatin Calcium combined with Silibinin in treatment of non-alcoholic fatty liver disease can effectively improve the liver function and serum lipid levels, and reduce the severity of fatty liver.
|
|
|
|
|
|
[1] Wong VW，Chu WC，Wong GL，et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese：a population study using proton-magnetic resonance spectroscopy and transient elastography [J]. Gut，2012，61（3）：409-415.
[2] Jessop AB，Hom JK，Burke M. Variation in the Viral Hepatitis and HIV Policies and Practices of Methadone Maintenance Programs [J]. J Addict Med，2017. doi: 10.1097/ADM.0000000000000296. [Epub ahead of print]
[3] Tiniakos DG，Vos MB，Brunt EM. Nonalcoholic fatty liver disease：pathology and pathogenesis [J]. Annu Rev Pathol，2010，5（10）：145-171.
[4] Sourianarayanane A，Arikapudi S，Mccullough AJ，et al. Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation [J]. Eur J Gastroenterol Hepatol，2017，29（4）：481-487.
[5] Petersen KF，Oral EA，Dufour S，et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy [J]. J Clin Invest，2002，109（10）：1345-1350.
[6] 裴强，王晓素，王宪波.非酒精性脂肪性肝炎发病机制的研究进展[J].临床肝胆病杂志，2008，24（4）：304-306.
[7] Razavi BM，Karimi G. Protective effect of silymarin against chemical-induced cardiotoxicity [J]. Iran J Basic Med Sci，2016，19（9）：916-923.
[8] Elyasi S，Hosseini S，Niazi MM，et al. Effect of Oral Silymarin Administration on Prevention of Radiotherapy Induced Mucositis：A Randomized，Double-Blinded，Placebo-Controlled Clinical Trial [J]. Phytother Res，2016，30（11）：1879-1885.
[9] Das S，Datta A，Bagchi C，et al. A Comparative Study of Lipid-Lowering Effects of Guggul and Atorvastatin Monotherapy in Comparison to Their Combination in High Cholesterol Diet-Induced Hyperlipidemia in Rabbits [J]. J Diet Suppl，2016，13（5）：495-504.
[10] Lin S，Huang J，Fu Z，et al. The effects of atorvastatin on the prevention of osteoporosis and dyslipidemia in the high-fat-fed ovariectomized rats [J]. Calcif Tissue Int，2015，96（6）：541-551.
[11] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].中华内科杂志，2010， 49（3）：18-20.
[12] Cuevas A，Fernandez C，Ferrada L，et al. HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals [J]. Basic Clin Pharmacol Toxicol，2016，118（4）：292-297.
[13] 范建高.国内外非酒精性脂肪性肝病诊疗指南的异同[J].临床肝胆病志，2012，26（7）：493-495.
[14] Oben JA，Mouralidarane A，Samuelsson AM，et al. Maternal obesity during pregnancy and lactation programs the development of offspring non-alcoholic fatty liver disease in mice [J]. J Hepatol，2010，52（6）：913-920.
[15] Morales M，Sendra C，Romero-Gomez M. Hepatitis B and NAFLD：Lives Crossed [J]. Ann Hepatol，2017，16（2）：185-187.
[16] 董姝，刘平，孙明瑜.非酒精性脂肪肝发病机制——“二次打击”学说研究进展[J].临床肝胆病杂志，2012，28（7）：551-555.
[17] 王哲，魏宁，赵英召，等.水飞蓟宾在非酒精性脂肪肝治疗中的作用[J].河北医药，2013，35（11）：1652-1653.
[18] 高月秋，刘波，文锐，等.水飞蓟宾胶囊在非酒精性脂肪肝治疗中的价值[J].中国实用医药，2013，8（10）：196.
[19] Rana H，Yadav SS，Reddy HD，et al. Comparative Effect of Insulin Sensitizers and Statin on Metabolic Profile and Ultrasonographical Score in Non Alcoholic Fatty Liver Disease [J]. J Clin Diagn Res，2016，10（8）：C19-C23.
[20] 秦永军，孙杰生，王炳元，等.脂肪肝与非脂肪肝患者血常规的差异分析[J].临床肝胆病杂志，2010，26（2）：163-166. |
|
|
|
